Evaluation of Breast Cancer Risk in a Multigenic Model Including Low Penetrance Genes Involved in Xenobiotic and Estrogen Metabolisms

Breast cancer has become the most frequent cancer among women in Westernized countries. The majority of breast cancers are due to low penetrance genes, which can act with environmental factors, particularly nutrition. Polymorphisms in gene coding for xenobiotic and estrogen metabolic pathways could increase individual cancer susceptibility and lead to the indication of individuals at higher cancer risk. A population-based, case-control study consisting of 911 breast cancer cases and 1,000 healthy control cases was performed. The association between 11 single nucleotide polymorphisms (SNP) in 7 genes and breast cancer risk was investigated in a multigenic model. The CYP1B1-432 Leu-Val and Val-Val genotypes significantly increased risk [odds ratio (OR) = 1.23, 95% confidence interval (CI) = 1.08–1.39; OR = 1.51, 95% CI = 1.17–1.94, respectively] similarly as observed with CYP1B1-453 (Asn-Ser genotype: OR = 1.17, 95% CI = 1.00–1.37; Ser-Ser genotype: OR = 1.38, 95% CI = 1.00–1.89). We showed that catechol-O-methyltransferase (COMT) could modulate the risk conferred by CYP1B1, ESR, GSTP1, and NAT2 acetylation phenotype. Additionally, a higher risk conferred by the variant for COMT was noted only for individuals presenting a high waist-to-hip ratio (COMT Val-Met, OR = 1.60, 95% CI = 1.04–2.44; COMT Met-Met, OR = 1.57, 95% CI = 0.98–2.53), suggesting a relationship with abdominal adiposity. In conclusion, COMT constitutes a crucial element in estrogen metabolism by regulating carcinogen metabolites elimination and, consequently, is a major factor in breast cancer risk.

[1]  L. Kuller,et al.  Anthropometry and Breast Cancer Risk in Nigerian Women , 2006, The breast journal.

[2]  X. Shu,et al.  Polymorphisms in CYP1A1 and breast carcinoma risk in a population‐based case–control study of Chinese women , 2005, Cancer.

[3]  Chen-Yang Shen,et al.  Breast cancer risk associated with genotype polymorphism of the catechol estrogen‐metabolizing genes: A multigenic study on cancer susceptibility , 2005, International journal of cancer.

[4]  B. Ponder,et al.  Polymorphisms associated with circulating sex hormone levels in postmenopausal women. , 2005, Journal of the National Cancer Institute.

[5]  R. Dumitrescu,et al.  Understanding breast cancer risk ‐ where do we stand in 2005? , 2005, Journal of cellular and molecular medicine.

[6]  P. Boyle,et al.  Serum polychlorinated biphenyls, cytochrome P-450 1A1 polymorphisms, and risk of breast cancer in Connecticut women. , 2004, American journal of epidemiology.

[7]  A. Folsom,et al.  CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: no association in the ARIC study. , 2004, Cancer letters.

[8]  Y. Miyoshi,et al.  Polymorphisms of estrogen synthesizing and metabolizing genes and breast cancer risk in Japanese women. , 2003, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[9]  K. Humphreys,et al.  Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. , 2003, Carcinogenesis.

[10]  A. Hirvonen,et al.  Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. , 2003, Mutation research.

[11]  D. Noh,et al.  Genetic polymorphisms of cytochrome P450 19 and 1B1, alcohol use, and breast cancer risk in Korean women , 2003, British Journal of Cancer.

[12]  D. Hein Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. , 2002, Mutation research.

[13]  A. Daly,et al.  Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population , 2002, Archives of Toxicology.

[14]  C. V. de Moura Gallo,et al.  CYP1A1, GSTM1, and GSTT1 polymorphisms and breast cancer risk in Brazilian women. , 2002, Cancer letters.

[15]  G. Colditz,et al.  Association of CYP1B1 polymorphisms and breast cancer risk. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[16]  E. D. de Vries,et al.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility , 2002, Journal of medical genetics.

[17]  N. Roodi,et al.  Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. , 2001, Cancer research.

[18]  C. Junien [Colon cancer and nutritional genetics: modifier genes]. , 2001, Annales de medecine interne.

[19]  A. LaCroix,et al.  Genetic susceptibility to breast cancer in French‐Canadians: Role of carcinogen‐metabolizing enzymes and gene–environment interactions , 2001, International journal of cancer.

[20]  Monique Girard,et al.  Sem : un outil de gestion informatique et statistique adapté à la recherche en cancérologie , 2000 .

[21]  N. Roodi,et al.  Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. , 2000, Cancer research.

[22]  O. Gotoh,et al.  Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. , 2000, Pharmacogenetics.

[23]  X. Shu,et al.  Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[24]  B Rosner,et al.  Waist circumference, waist:hip ratio, and risk of breast cancer in the Nurses' Health Study. , 1999, American journal of epidemiology.

[25]  B. Ponder,et al.  A Systematic Review Of Genetic Polymorphisms and Breast Cancer Risk 1 , 2000 .

[26]  Chen-Yang Shen,et al.  Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. , 1999, Cancer research.

[27]  R. Sinha,et al.  Diet, genetic susceptibility and human cancer etiology. , 1999, The Journal of nutrition.

[28]  N. Roodi,et al.  Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. , 1998, Cancer research.

[29]  D. Bell,et al.  Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer. , 1998, Journal of the National Cancer Institute.

[30]  W. Willett,et al.  Cigarette smoking, cytochrome P450 1A1 polymorphisms, and breast cancer risk in the Nurses' Health Study. , 1998, Cancer research.

[31]  J. Palmgren,et al.  Body‐size indicators and risk of breast cancer according to menopause and estrogen‐receptor status , 1996, International journal of cancer.

[32]  K. Keyomarsi,et al.  Expression of cytochromes P450 in human breast tissue and tumors. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[33]  E. Taioli,et al.  Functional significance of different human CYP1A1 genotypes. , 1994, Carcinogenesis.

[34]  K. Buetow,et al.  Genetics of CYP1A1: coamplification of specific alleles by polymerase chain reaction and association with breast cancer. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[35]  R. Ballard-Barbash Anthropometry and breast cancer. Body size‐a moving target , 1994, Cancer.

[36]  D. Parkin International variation , 2004, Oncogene.

[37]  F. Kwiatkowski,et al.  [Sem: a suitable statistical software adaptated for research in oncology]. , 2000, Bulletin du cancer.

[38]  M. Doll,et al.  Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[39]  T Foitzi,et al.  Allelic discrimination using fluorogenic probes and the 5' nuclease assay , 1999 .